Navigation Links
Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Date:11/5/2008

CALGARY, Nov. 5 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), will host a conference call and webcast on Thursday, November 6, 2008 at 11:00 a.m. MT (1:00 p.m. ET) to update investors on clinical trial results in its U.S. Phase II trial for patients with bone and soft tissue sarcomas metastatic to the lung. The results are scheduled to be presented November 6, 2008 at the Chemotherapy Foundation Symposium XXVI in New York.

To access the conference call by telephone, dial 1-416-915-5651 or 1-800-732-6179. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2471700, or through the Company's website at http://www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at http://www.oncolyticsbiotech.com and will also be available by telephone through November 13, 2008. To access the telephone replay, dial 1-416-640-1917 or 1-877-289-8525 and enter reservation number 21288636 followed by the number sign.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release c
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Men’s skin is biologically different than women’s ... and has been known to react more aggressively when hormones ... far from puberty, other acne causing factors like P.acnes bacteria ... threatening skin with unsightly acne scars. Adult acne treatment, Probiotic ... on how to reduce and prevent acne scarring. , ...
(Date:5/17/2013)... 17, 2013 Tooth decay is an epidemic ... signs of the disease. The World Health Organization says that ... of adults have cavities. What are the long-term effects of ... a strong connection between the oral bacterial imbalance and serious ... so rampant, yet it is also 100% preventable? Answer: there ...
(Date:5/16/2013)... A new selection of laboratory ... is designed to meet the dynamic needs of ... new Cole-Parmer® MS-3400 Centrifuges are clinical ... They ensure a powerful and complete separation of ... standard four-place swinging buckets hold 50-mL tubes. With ...
(Date:5/16/2013)... Scientists at the Center for Learning and ... the California -based biopharmaceutical company Magceutics, ... for reversing memory decline in mice with Alzheimer,s Disease. ... improvement in advanced stage AD mice. The study is ... decline for advanced stage AD mice, and is also ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3Cole-Parmer Offers Enhanced Selection of Centrifuges 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3
... Verenium Corporation (Nasdaq: VRNM ), a ... today announced that it has entered into an agreement ... United States ("Ex-Im Bank") for two 18-month, secured revolving ... These new credit facilities will allow the Company ...
... 2011 PharmaVentures today announced the launch of ... Essential Deal Trends: Oncology 2011 . This new series ... and commercialising new drugs. The first report in the series ... active deal making therapeutic area in the pharmaceutical and biotechnology ...
... cell carcinomas are amongst the most frequent cancers in ... like many other human cancers, contain particular cancer cells, ... potential that sustain tumor growth. Little is known about ... High level of VEGF expression in skin cancer ...
Cached Biology Technology:Verenium Announces Up to $16 Million in New Secured Financings 2Verenium Announces Up to $16 Million in New Secured Financings 3Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals' New Publication Series; Essential Deal Trends 2Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals' New Publication Series; Essential Deal Trends 3New role for Vascular Endothelial Growth Factor in regulating skin cancer stem cells 2
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) ... diet and lifestyle. , Individuals suffering from ... strength, fatigue and poor quality of life. These ... remission. A randomized, double blind, placebo-controlled study found ... corresponded to significant relief of these symptoms. ...
(Date:5/17/2013)... MD (May 18, 2013) The AGA Research Foundation ... into the relationship between the gut microbiota, one of ... and disease. , The AGA Research Awards Panel ... from Massachusetts General Hospital and Harvard Medical School, Boston, ... recipient. Dr. Chan will receive $25,000 of funding, commencing ...
(Date:5/17/2013)... The State University of New Jersey, and City University ... called Visikol TM that effectively clears organisms to ... place of chloral hydrate, which is one of the ... tightly regulated by the Drug Enforcement Administration (DEA) due ... or clearing agents, are vital for viewing organisms under ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3
... University of Houston (UH) executed two license agreements ... Electronics. One agreement covers the intellectual property on ... that is developed under the Sponsored Research Agreement ... sponsored research program is led by Venkat Selvamanickam, ...
... Public Health and Sanitation, together with the Department of ... a renewed set of national policy guidelines to redouble ... interventions to work within the country,s health system. This ... diarrhoea has stalled. Contrary to what many Kenyans believe, ...
... with legends of European monarchs, frail heirs and one flamboyant ... the very treatments that can help can also put patients, ... an expensively produced protein that helps the blood to clot. ... and in a subset of those, it sets off an ...
Cached Biology News:SuperPower and UH sign high temperature superconducting wire license agreements 2Policy unveiled to combat diarrheal disease, a killer of Kenyan children 2Policy unveiled to combat diarrheal disease, a killer of Kenyan children 3Researchers harness the power of plants to fight hemophilia 2Researchers harness the power of plants to fight hemophilia 3Researchers harness the power of plants to fight hemophilia 4
... cellular imaging and analysis system is an ... for rapid acquisition and analysis of fluorescence ... ImageXpress is fast. Scanning an entire 384-well ... pixels), with two fluorescence images per well, ...
Without sodium bicarbonate. Sterile, Cell culture tested...
... Bovine IFNγ ELISPOT (enzyme-lined immunospot) Kit analyzes ... cell level. A spot forms at the ... counted (either using a dissection microscope or ... the number of cells added to the ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,515-8) ...
Biology Products: